Bio-Path Holdings (BPTH) has issued an announcement.
Bio-Path Holdings, Inc. recently announced their presentation of promising data from a Phase 2 study exploring the use of Prexigebersen in treating Acute Myeloid Leukemia. This significant development was shared at the esteemed European Hematology Association Congress, showcasing the company’s progress in the field of cancer treatment.
See more data about BPTH stock on TipRanks’ Stock Analysis page.
